(BSX) Boston Scientific - Overview
Stock: Stents, Defibrillators, Pacemakers, Catheters, Endoscopes
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 91.8% |
| Relative Tail Risk | -10.3% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.04 |
| Alpha | -38.93 |
| Character TTM | |
|---|---|
| Beta | 0.649 |
| Beta Downside | 0.653 |
| Drawdowns 3y | |
|---|---|
| Max DD | 30.18% |
| CAGR/Max DD | 0.58 |
Description: BSX Boston Scientific January 27, 2026
Boston Scientific (BSX) designs, manufactures and markets a broad array of interventional medical devices across two primary segments-MedSurg and Cardiovascular. Its MedSurg portfolio spans gastrointestinal, urological and neuromodulation products (e.g., biliary stents, single-use duodenoscopes, holmium laser systems, spinal cord stimulators), while its Cardiovascular line includes coronary and aortic valve therapies, the WATCHMAN FLX left-atrial appendage closure system, and a full suite of implantable cardiac rhythm devices and remote monitoring solutions.
According to the company’s FY 2025 filing (released March 2026), BSX generated $12.5 billion in revenue, up 6 % year-over-year, with an operating margin of 21 % and diluted EPS of $2.30. R&D spending remained steady at roughly 8 % of revenue (~$1.0 billion), supporting a pipeline that recently added a next-generation bio-absorbable vascular scaffold. On the macro side, U.S. healthcare expenditure is projected to grow ~4 % annually through 2028, driven by an aging population and expanding minimally invasive procedures-both trends that historically boost demand for Boston Scientific’s device categories. A potential headwind is the anticipated tightening of Medicare reimbursement for certain cardiac implantable devices, which could modestly pressure margins if not offset by product mix shifts.
For a deeper, data-driven view of how these dynamics translate into valuation metrics, you might find ValueRay’s analyst framework useful as a next step.
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income: 2.89b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 3.85 > 1.0 |
| NWC/Revenue: 13.48% < 20% (prev 3.11%; Δ 10.37% < -1%) |
| CFO/TA 0.11 > 3% & CFO 4.63b > Net Income 2.89b |
| Net Debt (12.05b) to EBITDA (4.91b): 2.45 < 3 |
| Current Ratio: 1.51 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.50b) vs 12m ago 0.38% < -2% |
| Gross Margin: 69.01% > 18% (prev 0.61%; Δ 6840 % > 0.5%) |
| Asset Turnover: 48.90% > 50% (prev 42.51%; Δ 6.39% > 0%) |
| Interest Coverage Ratio: 8.33 > 6 (EBITDA TTM 4.91b / Interest Expense TTM 354.0m) |
Altman Z'' 1.27
| A: 0.06 (Total Current Assets 8.04b - Total Current Liabilities 5.33b) / Total Assets 42.71b |
| B: 0.11 (Retained Earnings 4.90b / Total Assets 42.71b) |
| C: 0.07 (EBIT TTM 2.95b / Avg Total Assets 41.05b) |
| D: 0.0 (Book Value of Equity 0.0 / Total Liabilities 19.08b) |
| Altman-Z'' Score: 1.27 = BB |
What is the price of BSX shares?
Over the past week, the price has changed by -18.45%, over one month by -22.01%, over three months by -23.00% and over the past year by -27.38%.
Is BSX a buy, sell or hold?
- StrongBuy: 23
- Buy: 8
- Hold: 3
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the BSX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 107.8 | 41.3% |
| Analysts Target Price | 107.8 | 41.3% |
| ValueRay Target Price | 77.3 | 1.4% |
BSX Fundamental Data Overview February 07, 2026
P/E Forward = 21.7865
P/S = 5.7359
P/B = 4.786
P/EG = 0.7365
Revenue TTM = 20.07b USD
EBIT TTM = 2.95b USD
EBITDA TTM = 4.91b USD
Long Term Debt = 10.99b USD (from longTermDebt, two quarters ago)
Short Term Debt = 483.0m USD (from shortTermDebt, two quarters ago)
Debt = 12.05b USD (from shortLongTermDebtTotal, two quarters ago)
Net Debt = 12.05b USD (using Total Debt 12.05b, CCE unavailable)
Enterprise Value = 127.19b USD (115.14b + Debt 12.05b - (null CCE))
Interest Coverage Ratio = 8.33 (Ebit TTM 2.95b / Interest Expense TTM 354.0m)
EV/FCF = 33.69x (Enterprise Value 127.19b / FCF TTM 3.77b)
FCF Yield = 2.97% (FCF TTM 3.77b / Enterprise Value 127.19b)
FCF Margin = 18.80% (FCF TTM 3.77b / Revenue TTM 20.07b)
Net Margin = 14.40% (Net Income TTM 2.89b / Revenue TTM 20.07b)
Gross Margin = 69.01% ((Revenue TTM 20.07b - Cost of Revenue TTM 6.22b) / Revenue TTM)
Gross Margin QoQ = 74.50% (prev 69.93%)
Tobins Q-Ratio = 2.98 (Enterprise Value 127.19b / Total Assets 42.71b)
Interest Expense / Debt = 0.75% (Interest Expense 90.0m / Debt 12.05b)
Taxrate = 4.43% (31.0m / 700.0m)
NOPAT = 2.82b (EBIT 2.95b * (1 - 4.43%))
Current Ratio = 1.51 (Total Current Assets 8.04b / Total Current Liabilities 5.33b)
Debt / Equity = 0.51 (Debt 12.05b / totalStockholderEquity, two quarters ago 23.39b)
Debt / EBITDA = 2.45 (Net Debt 12.05b / EBITDA 4.91b)
Debt / FCF = 3.19 (Net Debt 12.05b / FCF TTM 3.77b)
Total Stockholder Equity = 22.45b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.04% (Net Income 2.89b / Total Assets 42.71b)
RoE = 12.87% (Net Income TTM 2.89b / Total Stockholder Equity 22.45b)
RoCE = 8.82% (EBIT 2.95b / Capital Employed (Equity 22.45b + L.T.Debt 10.99b))
RoIC = 8.28% (NOPAT 2.82b / Invested Capital 34.05b)
WACC = 7.59% (E(115.14b)/V(127.19b) * Re(8.31%) + D(12.05b)/V(127.19b) * Rd(0.75%) * (1-Tc(0.04)))
Discount Rate = 8.31% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.64%
[DCF Debug] Terminal Value 82.60% ; FCFF base≈3.05b ; Y1≈3.76b ; Y5≈6.41b
Fair Price DCF = 71.50 (EV 118.08b - Net Debt 12.05b = Equity 106.03b / Shares 1.48b; r=7.59% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 98.51 | EPS CAGR: 21.12% | SUE: 1.15 | # QB: 12
Revenue Correlation: 98.82 | Revenue CAGR: 16.04% | SUE: 0.04 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.79 | Chg30d=-0.006 | Revisions Net=+1 | Analysts=22
EPS current Year (2026-12-31): EPS=3.46 | Chg30d=-0.007 | Revisions Net=+1 | Growth EPS=+13.1% | Growth Revenue=+11.2%
EPS next Year (2027-12-31): EPS=3.92 | Chg30d=-0.004 | Revisions Net=+1 | Growth EPS=+13.4% | Growth Revenue=+10.6%